Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities - PubMed
2 hours ago
- #psoriatic arthritis
- #GLP-1 receptor agonists
- #immunometabolic therapy
- GLP-1RAs, originally for type 2 diabetes, show promise in treating psoriasis and psoriatic arthritis by improving disease severity and inflammatory markers.
- Benefits of GLP-1RAs like liraglutide and semaglutide extend beyond weight loss, indicating direct immunomodulatory effects.
- Limited evidence exists for PsA, with studies often having small samples and short follow-up; early PsA may be an optimal treatment window.
- Two open-label trials (NCT06588296 and NCT06864026) investigated ixekizumab with/without tirzepatide in PsA patients with obesity, showing improved disease activity and metabolic benefits.
- Future research should focus on validating GLP-1RA efficacy, especially in early PsA, through dedicated clinical studies.